Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNF 1819
Discontinued Product
NF 1819 (Cat. No. 5956) has been withdrawn from sale for commercial reasons.
Description: Potent and selective irreversible MAGL inhibitor; membrane permeable and brain penetrant
Chemical Name: (3R,4S)-rel-4-(1,3-Benzodioxol-5-yl)-3-(4-fluorophenyl)-1-[1-(1H)-1,2,4-triazol-1-carbonyl)-4-piperidinyl]-2-azetidinone
Purity: ≥98% (HPLC)
Biological Activity for NF 1819
NF 1819 is a potent and selective irreversible MAGL inhibitor (IC50 values are 0.25 and 7.4 nM at rMAGL and hMAGL, respectively). Exhibits 389-fold selectivity over hFAAH and exhibits minimal binding at CB receptors (IC50 > 10 μM). Alleviates symptoms in a MS in vivo model. Exhibits analgesic effects in an acute inflammatory pain model in vivo. Ameliorates neuropathic hypersensitivity induced by oxaliplatin (Cat. No. 2623). Displays high membrane permeability and brain penetrant.
Technical Data for NF 1819
| M. Wt | 463.46 |
| Formula | C24H22FN5O4 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1881244-28-5 |
| PubChem ID | 127032456 |
| InChI Key | XRIROGBLGLPXQI-FGZHOGPDSA-N |
| Smiles | FC1=CC=C([C@@H]2[C@@H](C3=CC=C4OCOC4=C3)N(C2=O)C5CCN(C(N6C=NC=N6)=O)CC5)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for NF 1819
References for NF 1819
References are publications that support the biological activity of the product.
Brindisi et al (20106) Development and pharmacological characterization of selective blockers of 2-arachidonoyl glycerol degradation with efficacy in rodent models of multiple sclerosis and pain. J.Med.Chem. 59 2612 PMID: 26888301
View Related Products by Target
View Related Products by Product Action
Keywords: NF 1819, NF 1819 supplier, NF1819, Potent, selective, irreversible, MAGL, inhibitors, inhibits, MS, multiple, sclerosis, analgesics, neuropathic, hypersensitivity, membrane, permeable, brain, penetrant, 5956, Tocris Bioscience
Citations for NF 1819
Citations are publications that use Tocris products.
Currently there are no citations for NF 1819.
Reviews for NF 1819
There are currently no reviews for this product. Be the first to review NF 1819 and earn rewards!
Have you used NF 1819?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Research Product GuideNew
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Glycolysis
- Tricarboxylic Acid Cycle
- Lipidogenesis
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Cannabinoid Receptor Ligands Scientific Review
Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.